Volume : 10, Issue : 03, March – 2023



Authors :

Manal Abdulaziz Murad, Dr. Heba Kamal Salim, Dr. Saad Abdullah Almutairi, Dr.Abdullah Daifuallah Althoubity, Dr. Ghofran Yaslam Bazahair, Dr. Reem Salem Mahfoudh, Dr. Mahmoud Salah Aldin Andijani, Dr. Omar Abdullah Basfar, Dr. Fahad Ahmed Almarshud, Dr. Suhail Umar Alsurayhi, Dr. Abdulrahman Abdullatif Mahyoub and Dr. Mohamed Ahmed Waznah

Abstract :

The most common neurological symptom is a headache, which may be a sign of something dangerous like a brain tumor or something relatively harmless like a migraine or tension headache. Although migraine is more common and more debilitating, most of population suffer from it. Since most of population are continuously under pressure, it was important to assess the prevalence of migraine headaches among this population. Lack of research concentrating on migraine headache among population encouraged this study.

Cite This Article:

Please cite this article in press Manal Abdulaziz Murad et al, Patients Satisfaction With Migraine Management By Family Physicians In Saudi Arabia Jeddah: A Cross-Sectional Study.., Indo Am. J. P. Sci, 2023; 10(03)..

Number of Downloads : 10


1. American Migraine Foundation. Top 10 Migraine Triggers. [Updated 2017; Accessed 2022 Nov 7]. Available from: https://americanmigrainefoundation.org/resource-library/top-10-migraine-triggers
2. Shaik MM, Hassan NB, Tan HL, Gan SH.. Quality of life and migraine disability among female migraine patients in a tertiary hospital in Malaysia. Biomed Res Int 2015; 2015: 523717.
3. AlHarbi FG, AlAteeq MA.. Quality of life of migraine patients followed in neurology clinics in Riyadh, Saudi Arabia. J Family Community Med 2020; 27: 37-45.
4. GBD 2016. Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol 2018; 17: 954-976.
5. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S.. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev 2017; 97: 553-622.
6. Adamantidis A, Salvert D, Goutagny R, Lakaye B, Gervasoni D, Grisar T, Luppi PH, Fort P. Sleep architecture of the melanin-concentrating hormone receptor 1-knockout mice. Eur J Neurosci 27: 1793–1800, 2008. 7. Adrian TE, Allen JM, Bloom SR, Ghatei MA, Rossor MN, Roberts GW, Crow TJ, Tatemoto K, Polak JM. Neuropeptide Y distribution in human brain. Nature 306: 584–586, 2013.
8. Afra J. Intensity dependence of auditory evoked cortical potentials in migraine. Changes in the peri-ictal period. Funct Neurol 20: 199–200, 2005.
9. Afridi S, Giffin NJ, Kaube H, Friston KJ, Ward NS, Frackowiak RSJ, Goadsby PJ. A PET study in spontaneous migraine. Arch Neurol 62: 1270–1275, 2005.
10. Afridi S, Giffin NJ, Kaube H, Goadsby PJ. A randomized controlled trial of intranasal ketamine in migraine with prolonged aura. Neurology 80: 642–647, 2013.
11. Afridi S, Kaube H, Goadsby PJ. Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain 110: 675–680, 2004.
12. Afridi S, Kaube H, Goadsby PJ. Occipital activation in glyceryl trinitrate-induced migraine with visual aura. J Neurol Neurosurg Psychiatry 76: 1158–1160, 2005.
13. Afridi S, Matharu MS, Lee L, Kaube H, Friston KJ, Frackowiak RSJ, Goadsby PJ. A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain 128: 932–939, 2005.
14. Ahn AH. On the temporal relationship between throbbing migraine pain and arterial pulse. Headache 50: 1507–1510, 2010.
15. Airy H. On a distinct form of transient hemiopsia. Philos Trans R Soc Lond 160: 247, 1870.
16. Aiyar N, Rand K, Elshourbagy NA, Zeng Z, Adamou JE, Bergsma DJ, Li Y. A cDNA encoding the calcitonin gene-related peptide type 1 receptor. J Biol Chem 271: 11325–11329, 1996.
17. Akerman S, Goadsby PJ. Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: relevance to migraine. Sci Transl Med 7: 1–11, 2015.
18. Akerman S, Goadsby PJ. The role of dopamine in a model of trigeminovascular nociception. J Pharmacol Exp Ther 314: 162–169, 2005.
19. Akerman S, Goadsby PJ. Topiramate inhibits cortical spreading depression in rat and cat: impact in migraine aura. Neuroreport 16: 1383–1387, 2005.
20. Akerman S, Hoffmann J, Goadsby PJ. A translational approach to studying triptan-induced reversal of established central sensitization of trigeminovascular neurons. Cephalalgia 33: 211, 2013.
21. Akerman S, Holland P, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nature Rev Neurosci 12: 570–584, 2011.
22. Akerman S, Holland PR, Goadsby PJ. Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons. J Pharmacol Exp Ther 320: 64–71, 2007.
23. Akerman S, Holland PR, Goadsby PJ. Mechanically-induced cortical spreading depression associated regional cerebral blood flow changes are blocked by Na+ ion channel blockade. Brain Res 1229: 27–36, 2008.
24. Akerman S, Holland PR, Lasalandra M, Goadsby PJ. Endocannabinoids in the brainstem modulate dural trigeminovascular nociceptive traffic via CB1 and “triptan” receptors: implications in migraine. J Neurosci 33: 14869–14877, 2013.
25. Akerman S, Holland PR, Lasalandra MP, Goadsby PJ. Oxygen inhibits neuronal activation in the trigeminocervical complex after stimulation of trigeminal autonomic reflex, but not via direct dural activation of trigeminal afferents. Headache 49: 1131–1143, 2009.
26. Akerman S, Holland PR, Summ O, Lasalandra MP, Goadsby PJ. A translational in vivo model of trigeminal autonomic cephalalgias: therapeutic characterization. Brain 135: 3664–3675, 2012.
27. Akerman S, Kaube H, Goadsby PJ. Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors. Br J Pharmacol 142: 1354–1360, 2004.
28. Akerman S, Kaube H, Goadsby PJ. Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J Pharmacol Exp Ther 309: 56–63, 2004.
29. Akerman S, Williamson DJ, Kaube H, Goadsby PJ. The effect of anti-migraine compounds on nitric oxide-induced dilation of dural meningeal vessels. Eur J Pharmacol 452: 223–228, 2002.
30. Akerman S, Williamson DJ, Kaube H, Goadsby PJ. Nitric oxide synthase inhibitors can antagonise neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br J Pharmacol 137: 62–68, 2002.
31. Akerman S, Williamson DJ, Kaube H, Goadsby PJ. Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br J Pharmacol 137: 62–68, 2002.